Gemtuzumab is a monoclonal IgG4-κ antibody that targets CD33 on leukemia cells. Researchers use it to create antibody-drug conjugates (ADCs), such as Gemtuzumab ozogamicin. This ADC combines a cytotoxic calicheamicin derivative with the antibody, delivering the drug directly to CD33-positive leukemia cells.
Key Features:
- Target Specificity: Binds to CD33 on leukemia cells.
- Mechanism of Action: Delivers calicheamicin to kill cancer cells.
- Molecular Characteristics: Monoclonal IgG4-κ antibody linked to calicheamicin.
Applications:
- Acute Myeloid Leukemia (AML): For CD33-positive AML.
- Antibody-Drug Conjugates (ADCs): Links drugs to antibodies for targeted therapy.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
